Skip to main content
Evidence Snapshot

Interleukin-8

CHEMBL2157 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T02:28:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2157
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Interleukin-8 as ChEMBL target CHEMBL2157, mapped to UniProt P10145. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Interleukin-8
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2157
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P10145
Interleukin-8
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Interleukin-8 matters

As of 2026-09-14

Interleukin-8 is reviewed as Interleukin-8 (UniProt P10145); Interleukin-8 shows clinical signal disease relevance led by chronic bronchitis. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 527 compounds, and 16 assays, with lead potency reaching pChEMBL 8.6.

Disease context
chronic bronchitis

Interleukin-8 shows clinical signal disease relevance led by chronic bronchitis. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABX-IL8.

Start review with chronic bronchitis because it currently carries clinical signal support. Linked drugs include ABX-IL8. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 527 compounds, and 16 assays for this target. The dominant activity type is IC50. CHEMBL6032444 is the current potency anchor at pChEMBL 8.6.

Use CHEMBL6032444 as the tractability anchor when discussing potency (pChEMBL 8.6).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 8.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Interleukin-8 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10145, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic bronchitis is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

527
Total Compounds
16
Total Assays
4
Approved Drugs
IC50: 312.0, KI: 14.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL6032444
 8.6 IC50 —
No preferred name
CHEMBL5765378
 8.5 IC50 —
No preferred name
CHEMBL5844552
 8.2 IC50 —
No preferred name
CHEMBL5747821
 8.1 IC50 —
No preferred name
CHEMBL5786724
 8.1 IC50 —

Approved Drugs

Structure Compound First Approval
DICLOFENAC
CHEMBL139
 1988
TOLMETIN
CHEMBL1020
 1976
INDOMETHACIN
CHEMBL6
 1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T02:28:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2157